Cefpirome

Cefpirome exhibits excellent in vitro antibacterial activity against most Enterobacteriaceae, methicillin (HY-121544)-sensitive staphylococci and streptococci, moderate activity against Pseudomonas aeruginosa, variable activity against anaerobes, and weak activity against methicillin-resistant staphylococci and Enterococcus faecalis^[1].
Cefpirome is stable to most plasmid-mediated and chromosome-mediated β-lactamases, except for extended-spectrum SHV enzymes, and retains activity against β-lactamase-producing, third-generation cephalosporin-resistant Enterobacteriaceae strains^[1].
Cefpirome exhibits rapid outer membrane permeability to Gram-negative bacteria, and has a high-affinity binding capacity to key penicillin-binding proteins in both Gram-negative and Gram-positive bacteria, which endows it with broad-spectrum antibacterial activity^[1].
Cefpirome (18 h) prevented the emergence of Enterobacter cloacaemutants at a concentration of 1 μg/mL, thereby defining a narrow mutant selection window between the MIC (0.125 μg/mL) and the mutant prevention concentration^[2].
Cefpirome (0.06-32 μg/mL; 18-24 h) potently inhibits clinically isolated strains of Enterobacteriaceae, with MIC₉₀ ≤ 0.5 μg/mL for most species. It exhibits activity against non-glucose-fermenting Gram-negative bacilli, as well as both Oxacillin (HY-B0925A)-susceptible and Oxacillin-resistant staphylococci (the MIC₉₀ is 1 μg/mL for Oxacillin-susceptible Staphylococcus aureus and 16 μg/mL for Oxacillin-resistant Staphylococcus aureus). Only a slight salt-dependent increase in MIC is observed for coagulase-negative staphylococci^[3].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.